ArticleDermatology and therapy2025

Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.

Brett King et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.